REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled Trial

Semaglutide in Adults with Type 1 Diabetes and Obesity.

Shah Viral N, Akturk Halis K, Kruger Davida, Ahmann Andrew, Bhargava Anuj, Bakoyannis Giorgos, Pyle Laura, Snell-Bergeon Janet K
NEJM evidence2025DOI: 10.1056/EVIDoa2500173

Citations

0

Subjects

Non-Human

Study Context

Randomized controlled trials are the gold standard for evaluating treatment efficacy. The randomized design minimizes bias, making findings more reliable for clinical decision-making.

Why This Matters

This research contributes to the growing body of evidence on semaglutide. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

Shah Viral N, Akturk Halis K, Kruger Davida et al.. (2025). Semaglutide in Adults with Type 1 Diabetes and Obesity.. NEJM evidence. https://doi.org/10.1056/EVIDoa2500173

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.